APPLIED GENETICS DISCOVERY Trademark
Trademark Overview
On Wednesday, June 6, 2001, a trademark application was filed for APPLIED GENETICS DISCOVERY with the United States Patent and Trademark Office. The USPTO has given the APPLIED GENETICS DISCOVERY trademark a serial number of 78067784. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, May 3, 2002. This trademark is owned by DzGenes. The APPLIED GENETICS DISCOVERY trademark is filed in the Pharmaceutical Products category with the following description:
Applied Genetics Discovery is attempting to convert the findings from its discovery research, determining genes causing the major diseases, into products and services to help the maximum number of patients in the shortest period of time. The Company has already filed a substantial number of provisional patents which it believes will become the basis for therapeutic drugs, diagnostics and treatment regimes utilizing already approved drugs for new indications. End Stage Renal Disease has been an area of primary focus since inception. Over time, the number of genetic diseases will be expanded to include a wider range of targets. The Company's focus will include Class 5, therapeutic drugs, where it believes it will be able to preliminarily determine targets that are implicated in major genetic based diseases, such as end stage renal disease. The goal is to identify how to prevent or to forstall the onset of major diseases.
General Information
| Serial Number | 78067784 |
| Word Mark | APPLIED GENETICS DISCOVERY |
| Filing Date | Wednesday, June 6, 2001 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Friday, May 3, 2002 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 1000 - Typeset: Word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Applied Genetics Discovery is attempting to convert the findings from its discovery research, determining genes causing the major diseases, into products and services to help the maximum number of patients in the shortest period of time. The Company has already filed a substantial number of provisional patents which it believes will become the basis for therapeutic drugs, diagnostics and treatment regimes utilizing already approved drugs for new indications. End Stage Renal Disease has been an area of primary focus since inception. Over time, the number of genetic diseases will be expanded to include a wider range of targets. The Company's focus will include Class 5, therapeutic drugs, where it believes it will be able to preliminarily determine targets that are implicated in major genetic based diseases, such as end stage renal disease. The goal is to identify how to prevent or to forstall the onset of major diseases. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, June 13, 2001 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | DzGenes |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Richmond Heights, MO 63117 |
Trademark Events
| Event Date | Event Description |
| Friday, May 3, 2002 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Monday, September 17, 2001 | NON-FINAL ACTION MAILED |
| Tuesday, August 14, 2001 | ASSIGNED TO EXAMINER |
